AUSTIN, TX: July 23, 2007 – Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the
Chat real-time with other investors about this DRRX news release, by clicking this link: http://www.stockwire.com/DRRX
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=DRRX
Durect Corp (Nasdaq:DRRX)
Current Price (4.49)
NEW YORK July 17- Drug delivery technology company Durect Corp. said Tuesday postoperative pain treatment candidate Posidur showed positive results in a midstage study. The successful Phase IIb clinical trial, with 122 patients, triggers an $8 million milestone payment from development partner Nycomed. The drug is aimed at treating postoperative pain in hernia patients. The drug candidate reduced pain and total consumption of supplemental opioid pain medications, compared with placebo. Durect Corporation, a specialty pharmaceutical company, engages in the development of pharmaceutical products based on its proprietary drug delivery technology platforms. The company's pharmaceutical systems enable optimized therapy for a given disease or patient population by controlling the rate and duration of drug administration. Its products that are under Phase II clinical trials include POSIDUR to deliver bupivacaine, an off-patent anesthetic agent; TRANSDUR-Sufentanil to deliver sufentanil; and TRANSDUR-Bupivacaine to provide continuous delivery of bupivacaine for up to three days from a single application. The company's other products include Memryte that is under Truncated Phase III clinical trials, to deliver the peptide leuprolide acetate to treat Alzheimer's disease; Remoxy that is under Phase III clinical trials, to decrease the potential for oxycodone abuse; and CHRONOGESIC (sufentanil) pain therapy system, under system redesign, to continuously deliver sufentanil for an extended duration. The company also involves in the research and development of additional pharmaceutical systems in various therapeutic areas, including chronic pain, central nervous system disorders, and cardiovascular disease based on its proprietary drug delivery platform technologies. In addition, it manufactures and sells osmotic pumps used in laboratory research, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, the company designs, develops, and manufactures standard and custom biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. Durect Corporation was founded in 1998 and is headquartered in Cupertino, California.
Chat real-time with other investors about this FXPE news release, by clicking this link: http://www.stockwire.com/FXPE
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=FXPE
Fox Petroleum Inc. (OTC BB:FXPE)
Current Price (2.33)
LONDON--July 18--Fox Petroleum Inc. (OTCBB:FXPE - News; hereafter "FOX") has commenced an aggressive exploration program in and near Prudhoe Bay, Alaska. Fox has appointed a professional Geological Consultant to co-ordinate the initial stages of the program which is focused on defining several target drill sites within the FOX leases by the end of the calendar year. Based on geological assessments of property acreage, the Geological Advisor has identified numerous areas of interest. As a result, Fox is currently in the advanced stages of the contract placement process for the acquisition of additional seismic data. Once this data is acquired, it will be analyzed alongside the existing portfolio of geophysical surveys and well drilling and testing activities that have already taken place in or around the leases. Fox anticipates having all of the necessary seismic data within the next 60 days.
Chat real-time with other investors about this ESMC news release, by clicking this link: http://www.stockwire.com/ESMC
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=ESMC
Escalon Medical Corp (Nasdaq:ESMC)
Current Price (6.05)
WAYNE, Pa-- July 19-- Escalon Medical Corp. said Tuesday its Drew Scientific unit received Food and Drug Administration approval for its bodily fluids analysis system. The Trilogy Analyzer is intended for use in analyzing glucose, creatinine and urea nitrogen in serum.
Escalon Medical Corp., together with its subsidiaries, engages in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes, hematology, and vascular access. It provides instruments for blood cell counting and blood analysis; and supplies the reagent and other consumable materials needed to operate the instruments. The company also sells diabetic testing products, including DS5 that measures long-term glucose control in diabetic patients; and Hb-Gold, which provides for in vitro measurement of certain genetic diseases of the blood. In addition, it offers equipment for use in the field of human and veterinary hematology. Further, the company manufactures and markets ultrasound systems for diagnostic or biometric applications in ophthalmology, including A-Scans, B-Scans, High frequency B-Scans, and pachymeters. Escalon Medical also offers vascular access products, including PD Access and SmartNeedle lines of monitors, and Doppler-guided bare needles and infusion needles, used to locate desired vessels for access. In addition, the company provides ophthalmic surgical products to vitreoretinal ophthalmic surgeons; distributes intraocular gas products, C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; light sources, fiber optic probes, illuminated tissue manipulators, and CFA camera system. Further, it markets viscous fluid transfer systems and related disposable syringe products. The company offers its products to medical institutions, educational institutions, ophthalmologists, physician and veterinary office laboratories, and surgeons. It operates in the United States, the United Kingdom, and Europe. Escalon Medical was incorporated in 1987 and is based in Wayne, Pennsylvania.
Chat real-time with other investors about this IWEB news release, by clicking this link: http://www.stockwire.com/IWEB
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=IWEB
IceWEB, Inc. (OTC BB:IWEB)
Current Price (0.63)
HERNDON, Va.--July 18--IceWEB, Inc., www.iceweb.com (OTC BB:IWEB - News), announced today that it has been tasked by a US Government Agency to provide "two-factor authentication" for the agency's internal networks. The value of the contract award is $240,000. IceWEB, Inc., together with its subsidiaries, provides hosted software applications and network infrastructure solutions to small and medium-sized businesses, non-profit organizations, and government organizations in the United States. It offers hosted Web-based collaboration solutions that enable organizations to establish Internet, Intranet, and email/collaboration services. The company's online products and services include IceMAIL that provides a network hosted groupware, email, calendaring, and collaboration solution; IcePORTAL which enables to share and manage announcements, tasks, events/calendars, document libraries, pictures, and discussion threads through a single Web-based portal; and IceVISTA that provides Web hosting services. It also offers LearningStream.com, an online business education portal that offers subscription-based online classes to consumers and corporate customers. In addition, the company provides network infrastructure security solutions, such as access control, email security, intrusion detection, firewall, authentication, PKI, encryption, and traffic filtering products and services to protect the network infrastructure. Further, it offers consulting services, including network infrastructure, enterprise email/collaboration, and Internet/Intranet portal implementation and support services. IceWEB sells its products and services through direct sales force and online marketing. The company was founded in 2000 and is headquartered in Herndon, Virginia.
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
Stockwire Research Group, Inc. .
512.358.8440 .
info@stockwire.com .
